Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meropenem/vaborbactam - Melinta Therapeutics

Next Previous
Search
Drug Profile

Meropenem/vaborbactam - Melinta Therapeutics

Alternative Names: Carbavance™; Meropenem and vaborbactam; Meropenem trihydrate/vaborbactam; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014; Vabomere; Vaborem

Latest Information Update: 25 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer Melinta Therapeutics; Menarini; Rempex Pharmaceuticals; US Department of Health and Human Services; Xediton Pharmaceuticals
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bacteraemia; Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections; Ventilator associated pneumonia
  • Preregistration Pneumonia

Most Recent Events

  • 18 Mar 2025 Phase-II clinical trials in Pyelonephritis (In infants, In children) in USA (IV) (NCT06672978)
  • 18 Mar 2025 Phase-II clinical trials in Urinary tract infections (In infants, In children, Complicated) in USA (IV) (NCT06672978)
  • 30 Dec 2024 Preregistration for Nosocomial pneumonia in Canada (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top